News
TevaCanada2

Teva and Neos settle over Cotempla patent dispute

Teva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over the Israeli firm's generic version of Neos’ ADHD drug Cotempla XR-OD

News
Conceptual image of a head with cog gears as brain.

BioXcel's agitation drug gets FDA Fast Track

The FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting from neurological and psychiatric disorders like Alzheimer's and schizo

News

Press Releases

Views & Analysis

Newsletters and Deep Dive
digital magazine

Webinars

Podcasts

Video

White Papers

Spotlight on
Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Debates & Insight
PMA 2015 2016
Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Debates & Insight

Partner Content